Insider Financial icon

Why Intellia Therapeutics Stock Is a “Strong Buy”

Why Intellia Therapeutics Stock Is a “Strong Buy” With Caveats

Apart from artificial intelligence (AI) and cryptocurrency, genome editing research and development has long been a popular stock on Wall Street. Intellia Therapeutics (NASDAQ:NTLA) just earned a critical regulatory green light in this field, propelling Intellia Therapeutics stock higher. Analysts rate the biotechnology firm as a “Strong Buy,” but it still demands extensive due diligence […]